These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17020798)

  • 1. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005).
    Deshpande LM; Rhomberg PR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):367-72. PubMed ID: 17020798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance.
    Jones RN; Kirby JT; Rhomberg PR
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):203-13. PubMed ID: 18329835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004).
    Deshpande LM; Jones RN; Fritsche TR; Sader HS
    Microb Drug Resist; 2006; 12(4):223-30. PubMed ID: 17227206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
    Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of decreased susceptibility to carbapenems among Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii and investigation of carbapenemases.
    Lee HK; Park YJ; Kim JY; Chang E; Cho SG; Chae HS; Kang CS
    Diagn Microbiol Infect Dis; 2005 Aug; 52(4):331-6. PubMed ID: 15994052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004).
    Goossens H; Grabein B
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):257-64. PubMed ID: 16360549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):414-26. PubMed ID: 19833471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Apr; 54(4):249-57. PubMed ID: 16466890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae.
    Castanheira M; Sader HS; Jones RN
    Microb Drug Resist; 2010 Mar; 16(1):61-5. PubMed ID: 20192819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007).
    Castanheira M; Mendes RE; Rhomberg PR; Jones RN
    Microb Drug Resist; 2008 Sep; 14(3):211-6. PubMed ID: 18707552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sensitive and specific phenotypic assay for detection of metallo-β-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin.
    Giske CG; Gezelius L; Samuelsen Ø; Warner M; Sundsfjord A; Woodford N
    Clin Microbiol Infect; 2011 Apr; 17(4):552-6. PubMed ID: 20597925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
    Korten V; Ulusoy S; Zarakolu P; Mete B;
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003).
    Jones RN; Deshpande L; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):211-6. PubMed ID: 15246512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
    Rhomberg PR; Jones RN; Sader HS; Fritsche TR;
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
    Pascual A; Perea E; Alvarez M; Casal M; Garcia de Lomas J; Garcia Rodríguez JA; Martin R; Soria G; Zapardiel J;
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity?
    Tato M; Coque TM; Ruíz-Garbajosa P; Pintado V; Cobo J; Sader HS; Jones RN; Baquero F; Cantón R
    Clin Infect Dis; 2007 Nov; 45(9):1171-8. PubMed ID: 17918078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.